Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas
Published in The New England journal of medicine (26.05.2022)
Published in The New England journal of medicine (26.05.2022)
Get full text
Journal Article
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen R., Brahmer, Julie R., Swanson, Scott J., Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Liberman, Moishe, Vokes, Everett E., Taube, Janis M., Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y., Girard, Nicolas
Published in The New England journal of medicine (26.05.2022)
Published in The New England journal of medicine (26.05.2022)
Get full text
Journal Article
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL
Barr, Paul M., Saylors, Gene B., Spurgeon, Stephen E., Cheson, Bruce D., Greenwald, Daniel R., O'Brien, Susan M., Liem, Andre K.D., Mclntyre, Rosemary E., Joshi, Adarsh, Abella-Dominicis, Esteban, Hawkins, Michael J., Reddy, Anita, Di Paolo, Julie, Lee, Hank, He, Joyce, Hu, Jing, Dreiling, Lyndah K., Friedberg, Jonathan W.
Published in Blood (19.05.2016)
Published in Blood (19.05.2016)
Get full text
Journal Article
Abstract CT003: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment (tx) for resectable (IB-IIIA) non-small cell lung cancer (NSCLC) in the phase 3 CheckMate 816 trial
Forde, Patrick M., Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M., Felip, Enriqueta, Broderick, Stephen, Brahmer, Julie, Swanson, Scott J., Kerr, Keith, Wang, Changli, Saylors, Gene B., Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke-Neng, Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Girard, Nicholas
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Published in Cancer research (Chicago, Ill.) (01.07.2021)
Get full text
Journal Article
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non–small-cell lung cancer
Forde, Patrick M, Spicer, Jonathan, Lu, Shun, Provencio, Mariano, Mitsudomi, Tetsuya, Awad, Mark M, Felip, Enriqueta, Broderick, Stephen R, Brahmer, Julie R, Swanson, Scott J, Kerr, Keith, Wang, Changli, Ciuleanu, Tudor-Eliade, Saylors, Gene B, Tanaka, Fumihiro, Ito, Hiroyuki, Chen, Ke Neng, Liberman, Moishe, Vokes, Everett E, Taube, Janis M, Dorange, Cecile, Cai, Junliang, Fiore, Joseph, Jarkowski, Anthony, Balli, David, Sausen, Mark, Pandya, Dimple, Calvet, Christophe Y, Girard, Nicolas
Published in Future oncology (London, England) (01.03.2023)
Published in Future oncology (London, England) (01.03.2023)
Get full text
Journal Article
Improved Outcomes in Intermediate- and High-Risk Aggressive Non-Hodgkin Lymphoma after Autologous Hematopoietic Stem Cell Transplantation Substituting Intravenous for Oral Busulfan in a Busulfan, Cyclophosphamide, and Etoposide Preparative Regimen
Aggarwal, Charu, Gupta, Sameer, Vaughan, William P., Saylors, Gene B., Salzman, Donna E., Katz, Rhonda O., Nance, Amy G., Tilden, Arabella B., Carabasi, Matthew H.
Published in Biology of blood and marrow transplantation (01.07.2006)
Published in Biology of blood and marrow transplantation (01.07.2006)
Get full text
Journal Article
Abstract CT012: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial
Girard, Nicolas, Spicer, Jonathan, Provencio, Mariano, Lu, Shun, Broderick, Stephen, Awad, Mark M., Mitsudomi, Tetsuya, Kerr, Keith, Brahmer, Julie, Swanson, Scott J., Felip, Enriqueta, Wang, Changli, Saylors, Gene B., Chen, Ke-Neng, Tanaka, Fumihiro, Liberman, Moishe, Dorange, Cecile, Mahmood, Javed, Cai, Junliang, Forde, Patrick M.
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Published in Cancer research (Chicago, Ill.) (15.06.2022)
Get full text
Journal Article